Article
Morindone as a potential therapeutic compound targeting TP53 and KRAS mutations in colorectal cancer cells.
Chemico-biological interactions - 1 Apr 2024
Chee Cheok Wui, Mohd Hashim Najihah, Nor Rashid Nurshamimi
Abstract excerpt
There is an increasing demand for anticancer agent in treating colorectal cancer (CRC) with frequently mutated TP53 and KRAS genes. Phytochemical compounds are suitable as chemoprevention for CRC since dietary factor is a major risk factor. Anthraquinones from Morinda citrifolia L. were previously reported with various pharmacological properties. Various in vitro experiments were conducted to investigate the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
